STK11 mutation
|
NSCLC
|
STK11 mutation
|
NSCLC
|
Immunotherapy Resistant: C3 – Early Trials
Lung Cancer - 5 days (New C3)
|
Immunotherapy Resistant: C3 – Early Trials
Lung Cancer - 5 days - (New C3)
|
STK11 mutation
|
NSCLC
|
STK11 mutation
|
NSCLC
|
nivolumab Resistant: B - Late Trials
|
nivolumab Resistant: B - Late Trials
|
STK11 mutation
|
NSCLC
|
STK11 mutation
|
NSCLC
|
DRP-104 Sensitive: B - Late Trials
|
DRP-104 Sensitive: B - Late Trials
|
STK11 mutation
|
NSCLC
|
STK11 mutation
|
NSCLC
|
durvalumab Resistant: B - Late Trials
|
durvalumab Resistant: B - Late Trials
|
STK11 mutation
|
NSCLC
|
STK11 mutation
|
NSCLC
|
atezolizumab Resistant: B - Late Trials
|
atezolizumab Resistant: B - Late Trials
|
STK11 mutation
|
NSCLC
|
STK11 mutation
|
NSCLC
|
BGB324 Sensitive: B - Late Trials
|
BGB324 Sensitive: B - Late Trials
|
STK11 mutation
|
NSCLC
|
STK11 mutation
|
NSCLC
|
pembrolizumab + BGB324 Sensitive: B - Late Trials
|
pembrolizumab + BGB324 Sensitive: B - Late Trials
|
STK11 mutation
|
NSCLC
|
STK11 mutation
|
NSCLC
|
bevacizumab + atezolizumab Sensitive: B - Late Trials
|
bevacizumab + atezolizumab Sensitive: B - Late Trials
|
STK11 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
STK11 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
docetaxel Resistant: C3 – Early Trials
|
docetaxel Resistant: C3 – Early Trials
|
STK11 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
STK11 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
atezolizumab Resistant: C3 – Early Trials
|
atezolizumab Resistant: C3 – Early Trials
|
STK11 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
STK11 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
camrelizumab + rivoceranib Sensitive: C3 – Early Trials
|
camrelizumab + rivoceranib Sensitive: C3 – Early Trials
|
STK11 mutation
|
NSCLC
|
STK11 mutation
|
NSCLC
|
pembrolizumab Resistant: C3 – Early Trials
|
pembrolizumab Resistant: C3 – Early Trials
|
STK11 mutation
|
NSCLC
|
STK11 mutation
|
NSCLC
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
STK11 mutation
|
NSCLC
|
STK11 mutation
|
NSCLC
|
cetuximab + avelumab Resistant: C3 – Early Trials
|
cetuximab + avelumab Resistant: C3 – Early Trials
|
STK11 mutation
|
LUAD
|
STK11 mutation
|
LUAD
|
Immunotherapy Resistant: C3 – Early Trials
|
Immunotherapy Resistant: C3 – Early Trials
|
STK11 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
STK11 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
durvalumab + CP-675206 Resistant: C3 – Early Trials
|
durvalumab + CP-675206 Resistant: C3 – Early Trials
|
STK11 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
STK11 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
durvalumab Resistant: C3 – Early Trials
|
durvalumab Resistant: C3 – Early Trials
|
STK11 mutation
|
Cervical Cancer
|
STK11 mutation
|
Cervical Cancer
|
anlotinib + sintilimab Resistant: C3 – Early Trials
|
anlotinib + sintilimab Resistant: C3 – Early Trials
|
STK11 mutation
|
Solid Tumor
|
STK11 mutation
|
Solid Tumor
|
Immunotherapy Resistant: C3 – Early Trials
|
Immunotherapy Resistant: C3 – Early Trials
|
STK11 mutation
|
Pituitary Gland Carcinoma
|
STK11 mutation
|
Pituitary Gland Carcinoma
|
temozolomide + capecitabine Resistant: C4 – Case Studies
|
temozolomide + capecitabine Resistant: C4 – Case Studies
|
STK11 mutation
|
Pituitary Gland Carcinoma
|
STK11 mutation
|
Pituitary Gland Carcinoma
|
everolimus Sensitive: C4 – Case Studies
|
everolimus Sensitive: C4 – Case Studies
|
STK11 mutation
|
Pancreatic Cancer
|
STK11 mutation
|
Pancreatic Cancer
|
everolimus Sensitive: C4 – Case Studies
|
everolimus Sensitive: C4 – Case Studies
|
STK11 mutation
|
Lung Non-Small Cell Squamous Cancer
|
STK11 mutation
|
Lung Non-Small Cell Squamous Cancer
|
pembrolizumab Resistant: C4 – Case Studies
|
pembrolizumab Resistant: C4 – Case Studies
|
STK11 mutation
|
LUAD
|
STK11 mutation
|
LUAD
|
abemaciclib Sensitive: C4 – Case Studies
|
abemaciclib Sensitive: C4 – Case Studies
|
STK11 mutation
|
NSCLC
|
STK11 mutation
|
NSCLC
|
APG-115 Sensitive: D – Preclinical
|
APG-115 Sensitive: D – Preclinical
|
STK11 mutation
|
Lung Cancer
|
STK11 mutation
|
Lung Cancer
|
dasatinib + selumetinib + RTB101 Sensitive: D – Preclinical
|
dasatinib + selumetinib + RTB101 Sensitive: D – Preclinical
|
STK11 mutation
|
Lung Cancer
|
STK11 mutation
|
Lung Cancer
|
dasatinib Resistant: D – Preclinical
|
dasatinib Resistant: D – Preclinical
|
STK11 mutation
|
NSCLC
|
STK11 mutation
|
NSCLC
|
sirolimus Sensitive: D – Preclinical
|
sirolimus Sensitive: D – Preclinical
|
STK11 mutation
|
NSCLC
|
STK11 mutation
|
NSCLC
|
CI-1040 Sensitive: D – Preclinical
|
CI-1040 Sensitive: D – Preclinical
|
STK11 mutation
|
NSCLC
|
STK11 mutation
|
NSCLC
|
JQ-1 Resistant: D – Preclinical
|
JQ-1 Resistant: D – Preclinical
|